Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Director departure
ELITE PHARMACEUTICALS INC (ELTP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "]"
06/29/2023 8-K Quarterly results
Docs: "Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information Conference Call Scheduled for Friday, June 30 at 11:30 AM EDT"
02/14/2023 8-K Quarterly results
Docs: "Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information Conference Call Scheduled for Wednesday, February 15 at 11:30 AM EST"
11/15/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
06/29/2022 8-K Quarterly results
02/14/2022 8-K Quarterly results
Docs: "Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2021 and Provides Conference Call Information Conference Call Scheduled for Tuesday, February 15 at 11:30 AM EST"
08/16/2021 8-K Quarterly results
Docs: "Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2022 Ended June 30, 2021 and Provides Conference Call Information Conference Call Scheduled for Tuesday, August 17 at 11:30 AM EDT"
06/14/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
11/16/2020 8-K Quarterly results
Docs: "Elite Pharmaceuticals, Inc. Reports Financial Results For The Second Quarter of Fiscal Year 2021 Ended September 30, 2020 and Provides Conference Call Information Conference Call Scheduled for Tuesday, November 17 at 11:30 AM EST"
08/17/2020 8-K Quarterly results
06/29/2020 8-K Quarterly results
Docs: "Elite Pharmaceuticals, Inc. Reports Financial Results for The Fiscal Year Ended March 31, 2020 and Provides Conference Call Information Conference Call Scheduled for Tuesday, June 30th at 11:30 AM EDT"
02/10/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/09/2019 8-K Quarterly results
06/21/2019 8-K Quarterly results
Docs: "Dianne Will, Investor Relations 518-398-6222"
02/11/2019 8-K Quarterly results
11/09/2018 8-K Quarterly results
Docs: "Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2019 Ended September 30, 2018 and Provides Conference Call Information Conference Call Scheduled for Monday, November 12 th at 11:30 AM EST Northvale, NJ – November 9, 2018: Elite Pharmaceuticals, Inc. , a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the second quarter of fiscal year 2019 ended September 30, 2018 . Consolidated revenues for the Second Quarter were $1.4 million, a decrease of approximately 16% as compared to revenues for the comparable quarter of the prior fiscal year. The decrease in revenues was largely attributed to lower revenues received from the manufacture of generic methadone, hydromorphone and phentermi..."
08/09/2018 8-K Quarterly results
Docs: "For Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations, 518-398-6222"
06/14/2018 8-K Quarterly results
Docs: "For Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations, 518-398-6222"
02/09/2018 8-K Quarterly results
Docs: "For Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations, 518-398-6222"
11/09/2017 8-K Quarterly results
Docs: "For Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations, 518-398-6222"
08/09/2017 8-K Quarterly results
Docs: "For Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations, 518-398-6222"
06/14/2017 8-K Form 8-K - Current report
02/09/2017 8-K Quarterly results
Docs: "For Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations, 518-398-6222"
06/15/2016 8-K Form 8-K - Current report
02/23/2010 8-K Form 8-K - Current report
07/10/2008 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy